Date: 2013-10-29
Type of information:
phase: 1
Announcement: dosing of the first patient
Company: Boehringer Ingelheim (Germany)
Product: undisclosed Nanobody®
Action mechanism:
Disease: Alzheimer's disease
Therapeutic area: Neurodegenerative diseases
Country:
Trial details:
Latest
news: * On October 29, 2013, Ablynx has announced that its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody® for the treatment of Alzheimer\'s disease. The start of the Phase I study triggers a milestone payment of €5 million to Ablynx.The Phase I study involves a single-centre, partially randomised, single-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenous and subcutaneous injections with the Nanobody in healthy subjects. The trial is expected to recruit 80 healthy volunteers and results are anticipated during H2 2014.In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer\'s disease using Ablynx\'s Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.
